core protocol inclusion criteria: * be aged 18 years or older * have given written informed consent * be a member of one of the following vulnerable patients populations * dialysis - including in centre haemodialysis, home haemodialysis and peritoneal dialysis * kidney transplant receiving at least one of the immunosuppressive medications listed below * vasculitis (according to chapel hill consensus conference 2012 definitions) or systemic lupus erythematosus (sle) receiving at least one of the immunosuppressive medications listed below * glomerulonephritis (includes prior histological confirmation of any of the following conditions - minimal change nephropathy, focal segmental glomerulosclerosis (fsgs), iga nephropathy, primary membranous nephropathy, membranoproliferative glomerulonephritis or lupus nephritis) receiving at least one of the immunosuppressive medications listed below ciclosporin tacrolimus azathioprine mycophenolate mofetil or mycophenolic acid belatacept methotrexate tocilizumab abatacept leflunomide sirolimus prednisolone (current dose) \> 20mg daily for 8 weeks anti-tnf (infliximab, adalimumab, etanercept) belimumab cyclophosphamide (within the last 6 months) rituximab (in the last 12 months) or rituximab in the last 5 years and igg level \<5g/l alemtuzumab (in the last 12 months)

core protocol inclusion criteria: * be aged 18 years or older * have given written informed consent * be a member of one of the following vulnerable patients populations * dialysis - including in centre haemodialysis, home haemodialysis and peritoneal dialysis * kidney transplant receiving at least one of the immunosuppressive medications listed below * vasculitis (according to chapel hill consensus conference 2012 definitions) or systemic lupus erythematosus (sle) receiving at least one of the immunosuppressive medications listed below * glomerulonephritis (includes prior histological confirmation of any of the following conditions - minimal change nephropathy, focal segmental glomerulosclerosis (fsgs), iga nephropathy, primary membranous nephropathy, membranoproliferative glomerulonephritis or lupus nephritis) receiving at least one of the immunosuppressive medications listed below ciclosporin tacrolimus azathioprine mycophenolate mofetil or mycophenolic acid belatacept methotrexate tocilizumab abatacept leflunomide sirolimus prednisolone (current dose) \> 20mg daily for 8 weeks anti-tnf (infliximab, adalimumab, etanercept) belimumab cyclophosphamide (within the last 6 months) rituximab (in the last 12 months) or rituximab in the last 5 years and igg level \<5g/l alemtuzumab (in the last 12 months)

core protocol inclusion criteria: be aged 18 years or older have given written informed consent be a member of one of the following vulnerable patients populations dialysis - including in centre haemodialysis, home haemodialysis and peritoneal dialysis kidney transplant receiving at least one of the immunosuppressive medications listed below vasculitis (according to chapel hill consensus conference 2012 definitions) or systemic lupus erythematosus (sle) receiving at least one of the immunosuppressive medications listed below glomerulonephritis (includes prior histological confirmation of any of the following conditions - minimal change nephropathy, focal segmental glomerulosclerosis (fsgs), iga nephropathy, primary membranous nephropathy, membranoproliferative glomerulonephritis or lupus nephritis) receiving at least one of the immunosuppressive medications listed below ciclosporin tacrolimus azathioprine mycophenolate mofetil or mycophenolic acid belatacept methotrexate tocilizumab abatacept leflunomide sirolimus prednisolone (current dose) > 20mg daily for 8 weeks anti-tnf (infliximab, adalimumab, etanercept) belimumab cyclophosphamide (within the last 6 months) rituximab (in the last 12 months) or rituximab in the last 5 years and igg level <5g/l alemtuzumab (in the last 12 months)

core protocol inclusion criteria: be aged 18 years or older have given written informed consent be a member of one of the following vulnerable patients populations dialysis - including in centre haemodialysis, home haemodialysis and peritoneal dialysis kidney transplant receiving at least one of the immunosuppressive medications listed below vasculitis (according to chapel hill consensus conference 2012 definitions) or systemic lupus erythematosus (sle) receiving at least one of the immunosuppressive medications listed below glomerulonephritis (includes prior histological confirmation of any of the following conditions - minimal change nephropathy, focal segmental glomerulosclerosis (fsgs), iga nephropathy, primary membranous nephropathy, membranoproliferative glomerulonephritis or lupus nephritis) receiving at least one of the immunosuppressive medications listed below ciclosporin tacrolimus azathioprine mycophenolate mofetil or mycophenolic acid belatacept methotrexate tocilizumab abatacept leflunomide sirolimus prednisolone (current dose) > 20mg daily for 8 weeks anti-tnf (infliximab, adalimumab, etanercept) belimumab cyclophosphamide (within the last 6 months) rituximab (in the last 12 months) or rituximab in the last 5 years and igg level <5g/l alemtuzumab (in the last 12 months)

core protocol inclusion criteria: - be aged 18 years or older have given written informed consent be a member of one of the following vulnerable patients populations ○ dialysis - including in centre haemodialysis, home haemodialysis and peritoneal dialysis kidney transplant receiving at least one of the immunosuppressive medications listed below vasculitis (according to chapel hill consensus conference 2012 definitions) or systemic lupus erythematosus (sle) receiving at least one of the immunosuppressive medications listed below glomerulonephritis (includes prior histological confirmation of any of the following conditions - minimal change nephropathy, focal segmental glomerulosclerosis (fsgs), iga nephropathy, primary membranous nephropathy, membranoproliferative glomerulonephritis or lupus nephritis) receiving at least one of the immunosuppressive medications listed below ciclosporin tacrolimus azathioprine mycophenolate mofetil or mycophenolic acid belatacept methotrexate tocilizumab abatacept leflunomide sirolimus prednisolone (current dose) > 20mg daily for 8 weeks anti-tnf (infliximab, adalimumab, etanercept) belimumab cyclophosphamide (within the last 6 months) rituximab (in the last 12 months) or rituximab in the last 5 years and igg level <5g/l alemtuzumab (in the last 12 months)

core protocol inclusion criteria: - be aged 18 years or older have given written informed consent be a member of one of the following vulnerable patients populations ○ dialysis - including in centre haemodialysis, home haemodialysis and peritoneal dialysis kidney transplant receiving at least one of the immunosuppressive medications listed below vasculitis (according to chapel hill consensus conference 2012 definitions) or systemic lupus erythematosus (sle) receiving at least one of the immunosuppressive medications listed below glomerulonephritis (includes prior histological confirmation of any of the following conditions - minimal change nephropathy, focal segmental glomerulosclerosis (fsgs), iga nephropathy, primary membranous nephropathy, membranoproliferative glomerulonephritis or lupus nephritis) receiving at least one of the immunosuppressive medications listed below ciclosporin tacrolimus azathioprine mycophenolate mofetil or mycophenolic acid belatacept methotrexate tocilizumab abatacept leflunomide sirolimus prednisolone (current dose) > 20mg daily for 8 weeks anti-tnf (infliximab, adalimumab, etanercept) belimumab cyclophosphamide (within the last 6 months) rituximab (in the last 12 months) or rituximab in the last 5 years and igg level <5g/l alemtuzumab (in the last 12 months)

inclusion criteria: - be aged 18 years or older - have given written informed consent - be a member of one of the following vulnerable patients populations - dialysis - including in centre haemodialysis, home haemodialysis and peritoneal dialysis - kidney transplant receiving at least one of the immunosuppressive medications listed below - vasculitis (according to chapel hill consensus conference 2012 definitions) receiving at least one of the immunosuppressive medications listed below - glomerulonephritis* receiving at least one of the immunosuppressive medications listed below ciclosporin tacrolimus azathioprine mycophenolate mofetil or mycophenolic acid belatacept methotrexate tocilizumab abatacept leflunomide prednisolone (current dose) > 20mg daily for 8 weeks anti-tnf (infliximab, adalimumab, etanercept) belimumab cyclophosphamide (within the last 6 months) rituximab (in the last 12 months) alemtuzumab (in the last 12 months)

inclusion criteria: - be aged 18 years or older - have given written informed consent - be a member of one of the following vulnerable patients populations - dialysis - including in centre haemodialysis, home haemodialysis and peritoneal dialysis - kidney transplant receiving at least one of the immunosuppressive medications listed below - vasculitis (according to chapel hill consensus conference 2012 definitions) receiving at least one of the immunosuppressive medications listed below - glomerulonephritis* receiving at least one of the immunosuppressive medications listed below ciclosporin tacrolimus azathioprine mycophenolate mofetil or mycophenolic acid belatacept methotrexate tocilizumab abatacept leflunomide prednisolone (current dose) > 20mg daily for 8 weeks anti-tnf (infliximab, adalimumab, etanercept) belimumab cyclophosphamide (within the last 6 months) rituximab (in the last 12 months) alemtuzumab (in the last 12 months)